Outcomes of Simultaneous Kidney-Pancreas Transplantation in Patients with Type-I and Type-II Diabetes Mellitus

H. Shokouh-Amiri¹, M. S. Naseer¹, A. Palermini¹, D. Aultman¹, R. McMillan¹, S. Tandukar², N. Singh², G. Zibari¹

¹Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Health System, Shreveport, LA, ²Transplant Nephrology, John C. McDonald Regional Transplant Center - Willis Knighton Health System, Shreveport, LA

Meeting: 2021 American Transplant Congress

Abstract number: 1240

Keywords: Graft survival, Kidney/pancreas transplantation, Obesity, Outcome

Topic: Clinical Science » Pancreas » Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas and Islet: All Topics

Session Type: Poster Abstract

Session Date & Time: None. Available on demand.

Location: Virtual

*Purpose: UNOS approved simultaneous kidney-pancreas transplantation (SKPT) for type-II diabetes mellitus (DM) in Oct 2014. There is limited data comparing outcomes of SKPT in type-I versus type-II DM. The aim of this study was to measure the change in volume of SKPT since UNOS approved it for type-II DM patients and compare death-censored 5-year kidney and pancreas graft and patient survival between type-I and type-II DM patients undergoing SKPT.

*Methods: We conducted a single-center retrospective chart-review study on SKPT patients from Jan 2010 to Nov 2020 and collected data on patient demographics, BMI, c-peptide, HbA1c, and eGFR. Student’s t-test for continuous variables, Chi-square test for categorical variables, and Log rank test for survival analysis were done using SPSS.

*Results: Among 89 SKPT, 18 (all type-I DM) and 71 (41 type-I and 30 type-II DM) were done pre- and post-approval of SPKT for type-II DM respectively. This translated to an increase in SKPT from 3.6/year to 11.8/year (228% increase). There were no statistically significant differences in c-peptide and HbA1c levels pre- and 1-year post-SKPT. Patients with type-II DM were of older age and had higher BMI and eGFR 1-year post-SKPT. There were no statistically significant differences in death-censored kidney and pancreas graft and patient survival at 5-year post-SKPT.

Patient Demographics, Lab Parameters, and Survival Analysis
	DM type-I (n=59)	DM type-II (n=30)	P-Value
Age (Y), mean ± SD	40.2 ± 9.5	47.4 ± 8.8	<0.01
Male, % (n)	62.1 (36)	61.3 (19)	0.94
BMI (kg/m²) Pre-SKPT, mean ± SD	25.9 ± 4.2	27.0 ± 2.8	0.15
BMI (kg/m²) 1-Year Post-SKPT, mean ± SD	26.7 ± 4.6	32.0 ± 3.7	<0.01
eGFR (ml/min/1.73m²) Pre-SKPT, mean ± SD	13.0 ± 8.0	13.6 ± 9.3	0.83
eGFR (ml/min/1.73m²) 1-Year Post-SKPT, mean ± SD	62.0 ± 18.6	76.7 ± 22.6	0.04
Death-Censored 5-Year Kidney Graft/Pancreas Graft/Patient Survival, %	84.7/88.1/94.9	93.3/93.3/90.0	0.63/0.65/0.27

*Conclusions: Approval of SKPT for type-II DM by UNOS led to an increase in SKPT with no differences in graft or patient survival between patients with type-I and type-II DM.

To cite this abstract in AMA style:

Shokouh-Amiri H, Naseer MS, Palermini A, Aultman D, McMillan R, Tandukar S, Singh N, Zibari G. Outcomes of Simultaneous Kidney-Pancreas Transplantation in Patients with Type-I and Type-II Diabetes Mellitus [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-simultaneous-kidney-pancreas-transplantation-in-patients-with-type-i-and-type-ii-diabetes-mellitus/. Accessed May 16, 2025.

« Back to 2021 American Transplant Congress